The question that remains concerns the potential for VMAT-2 inhibitors to treat psychosis with a lower the risk of tardive dyskinesia and without the risk of inducing post-synaptic receptor supersensitivity. This evidence concerns the gene SLC18A2 and psychotic disorder.